Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Synutra is a nutrition and consumer health company best known for infant formula and nutritional products for infants, children, and adults, primarily serving the China market through a group structure with U.S. and Chinese operations. Historically, the public holding company was Synutra International, a Delaware-incorporated company headquartered in Rockville, Maryland and formerly listed on Nasdaq under the symbol SYUT. The company completed a founder-led going-private transaction in May 2017 and is no longer publicly traded. Synutra-related operating businesses remain active through brands and divisions such as Synutra Ingredients and Synutra Pure, which market dietary ingredients and supplements including chondroitin, collagen, calcium, and whey protein products. From a biotech analyst perspective, this is a commercial nutrition and consumer health business rather than a therapeutics developer, with no evident drug pipeline or clinical-stage R&D focus.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Synutra.